A glass heart holding a golden engine of pistons and gears with a ring of light looping around it.

MOTS-c Dosage: Human Data, Mouse Doses and the Schedules That Circulate Online

November 2, 2026

MOTS-c is a 16 amino acid peptide made by mitochondria, and it is heavily discussed online despite almost no human dosing data. There is no label dose and no published dosing study of the peptide itself in people. This page tables the one human course of a related analog, the mouse amounts that started the field, the community schedules that circulate, and where each number actually comes from.

Ask PeptideBlog about any peptide

Quick answer: MOTS-c has no approved dose. The only human administration data is for CB4211, a developer analog of MOTS-c, given as 25 mg under the skin once daily for 4 weeks in a small sponsor-reported trial.[10][11] Mouse studies used 0.5 to 50 mg/kg and cannot be converted into human amounts.[1][2][7] Online, the most-reported protocol is 5 to 10 mg injected 2 to 3 times a week for 4 to 10 weeks, plus 1 mg daily versions.[16][17] No source traces those numbers to a trial.

Figures on this page summarize amounts and schedules reported in published research, prescribing information or circulating online. Their inclusion documents what is reported and does not establish that a regimen is verified, safe, effective, or appropriate.

A glass heart holding a golden engine of pistons and gears with a ring of light looping around it.

Every studied or reported MOTS-c amount at a glance

The rows run from human data to animal data to community schedules. Mouse amounts are in milligrams per kilogram of body weight and community amounts are milligrams per injection, so the two are not comparable and are never converted here.

Swipe the table sideways to see every column.

MOTS-c and MOTS-c analog amounts: human trials, animal studies and non-trial sources
SourcePopulationRouteAmountFrequencyDurationEvidence category
Human exercise study (Reynolds 2021)10 sedentary healthy men, average age 24.5None given (endogenous measurement)No MOTS-c administeredNot applicableSingle exercise sessionHuman observational (Tier 2). Muscle MOTS-c rose 11.9-fold, plasma 1.6-fold during exercise[2]
CB4211 phase 1a (NCT03998514)65 healthy adultsSubcutaneous injection of a MOTS-c analogDoses not stated in the sources openedSingle doses (6 cohorts); once daily for 7 days (3 cohorts)1 to 7 daysRegistered human trial; sponsor-reported (Tier 2)[10][11][12]
CB4211 phase 1b (NCT03998514)23 randomized adults with obesity and NAFLD; 20 completedSubcutaneous injection of a MOTS-c analog25 mgOnce daily4 weeksRegistered human trial; sponsor-reported, not peer reviewed (Tier 2)[10][11][12]
MOTS-MET (NCT07505745)120 planned, adults with prediabetes, BMI 27 to 40Subcutaneous injectionDose not stated in the registry recordNot stated12 weeks, follow-up to week 16Registered human trial; recruiting; no results (Tier 2)[13]
Human dosing study of MOTS-c itselfNone identifiedNot applicableNo established or reliably sourced dosing information was identified.Not applicableNot applicableNo evidence category applies[15]
Lee 2015, miceNormal-diet CD-1 mice; high-fat-diet miceIntraperitoneal5 mg/kg/day (twice daily for 4 days); 0.5 mg/kg/day in high-fat-diet miceDaily4 days; 3 weeks and 8 weeks of dietPublished animal research (Tier 3)[1]
Reynolds 2021, miceYoung, high-fat-diet, 12 and 22 month old miceIntraperitoneal5 and 15 mg/kg/dayDaily; later 3 times per week2 weeks; late-life course from about 23.5 monthsPublished animal research (Tier 3)[2]
Yin 2020, miceMice, formalin pain testIntraperitoneal50 mg/kgDose-dependent effect reportedAcutePublished animal research (Tier 3)[7]
R13A-MOTS-c analog, miceMice after 20 Gy chest irradiationIntraperitoneal5 mg/kg (analog, not MOTS-c)Daily2 weeksPublished animal research (Tier 3)[9]
Lee 2015, cellsCultured cellsAdded to culture10 µMNot applicableNot applicableLaboratory research (Tier 4)[1]
Wiki dosing pageCommunity and wiki authorsSubcutaneous5 to 10 mg per injection2 to 3 times per week, or every 5 days4 to 6 weeks (20 or 30 day protocols), repeated 2 to 4 times per yearCommunity, vendor or clinic reported (Tier 6). The box cites nothing[16]
Wiki community page (40 reports)Self-reported usersSubcutaneous5 to 10 mg; 10 mg once weekly; 1 mg daily; titration from 200 mcg to 1000 mcg in 200 mcg steps every 2 weeks2 to 3 times per week; weekly; daily; titration4 to 10 weeks; up to 10 weeks; 4 to 8 weeks; 10 weeksCommunity, vendor or clinic reported (Tier 6)[17]
Substack author, no credentials statedUnspecifiedRoute not named0.5 to 1 mg daily start; 5 mg every 5 days (20 mg total); 10 mg weekly (40 mg total); 5 mg three times per week (60 to 90 mg total); 10 mg weekly (100 mg total)Per entry4 to 10 weeks; no more than 8 weeks on, 4 offCommunity, vendor or clinic reported (Tier 6). No citations[18]
Telehealth consent form (platform name withheld)Patients of one platformInjectableNo mg figure givenNot stated8 to 12 weeks, then a planned 4 week pauseCommunity, vendor or clinic reported (Tier 6). States a safe and effective human dose has not been established[20]
Peptide Dossier guideEducational site that states it sells nothingNot applicableRejects 5, 10 and 15 mg per day tiers and 5-on 2-off schedules as unsupportedRejects 8, 12 and 16 week cyclesNot applicableConflicting reports. The guide sides with the evidence gap[19]

CB4211 is the developer’s name for a MOTS-c analog; its exact structure is not given in the sources I opened, so it is not assumed to behave like MOTS-c.[10] The registry lists “Route: subcutaneous injection” for NCT07505745 with no dose or regimen text.[13] Wiki figures come from the Peptide Protocol Wiki, a community-run reference.

Where these figures come from

The most-reported human-use figure is 5 to 10 mg per injection, two to three times a week, for 4 to 6 weeks, repeated two to four times a year. It appears on the Peptide Protocol Wiki dosing page in a box with no citation, and the wiki’s community page, based on 40 reports, calls a near-identical pattern “most commonly reported” for 4 to 10 weeks.[16][17] A separate Substack post lists the same family of numbers, including 5 mg every 5 days for 20 mg total, and adds none of its own sources.[18]

I could not trace those figures to any experiment. They do not match a mouse dose, because mouse papers use milligrams per kilogram, and they do not match the one human analog trial, which used 25 mg daily.[1][2][10] The wiki also states that no human dosing protocols are established.[16] Its own mouse table credits “5 mg/kg” to Lee 2015 and Reynolds 2021, but Lee used 0.5 and 5 mg/kg/day and Reynolds used 5 and 15, so the table blurs the original papers.[1][2][16] When a convenient figure appears on several sites with no origin, the sites are copying one another, not confirming one another.

Human evidence is thinner than the volume of coverage suggests. The Reynolds paper includes a human arm, but it measured natural MOTS-c after exercise and injected nothing.[2] The only registered human injection program I found for a MOTS-c analog is the sponsor’s phase 1 trial.[10][11][12] Public Citizen’s July 2026 testimony to FDA’s advisory committee put it bluntly: no published human studies of MOTS-c itself, only rodent and cell data lasting weeks.[15]

Weight-based scaling is where the gap gets filled with assumption. The wiki runs an animal-to-human conversion and arrives at about 28.5 mg per dose for a 70 kg adult, then labels it “purely academic.”[16] I repeat that only to flag it. Mouse-to-human conversion has not been validated for this peptide, and the number matches no human data.

Peptide Dossier, an educational site that states it sells nothing, reviewed the circulating claims and rejected daily tiers of 5, 10 and 15 mg, “5-on 2-off” schedules, 8, 12 and 16 week cycles and a “several hour” half-life as unsupported. It also notes that NCT07505745 states no dose.[19][13] The half-life of about 4 hours that the Substack post states has no source.[18]

Technical identity

MOTS-c stands for mitochondrial open reading frame of the 12S rRNA-c. It is encoded in the DNA of the mitochondria, not the cell nucleus, which makes it unusual. Lee and colleagues at the University of Southern California described it in 2015, reporting that it acts mainly on skeletal muscle and activates AMPK, an energy-sensing enzyme.[1]

Swipe the table sideways to see every column.

MOTS-c identity
PropertyInformation
Primary nameMOTS-c (mitochondrial open reading frame of the 12S rRNA-c)[1]
Sequence (three letter)Met-Arg-Trp-Gln-Glu-Met-Gly-Tyr-Ile-Phe-Tyr-Pro-Arg-Lys-Leu-Arg[9][21]
Sequence (one letter)MRWQEMGYIFYPRKLR[28]
Length16 amino acids[1]
Molecular formulaC101H152N28O22S2 (free peptide)[28][29]. HHS Appendix B lists the acetate as C101H152N28O22S2·CH3COOH[21]
Molecular weightFree peptide 2174.62 g/mol[28]. Acetate 2234.64 g/mol[21]
CAS Registry Number1627580-64-6. Source: Wikipedia only; not confirmed in a chemical database[28]
PubChem CID146675088. The page listed the formula; other fields did not load[29]
UNII, DrugBank IDNot reliably established
Chemical modificationsNone for the natural peptide. The analogs CB4211 and R13A-MOTS-c are modified; CB4211’s structure is not given in the sources opened[9][10]
Half-life in humansNot reliably established
Primary biological targetAMPK activation and the folate cycle in muscle, per the discovery paper; nuclear gene effects in later work[1][2]
Developer or originatorChanghan Lee and Pinchas Cohen’s group, University of Southern California, 2015[1]. CohBar developed CB4211[10]
Development statusNo approved drug. Analog program discontinued per Public Citizen; a registered phase 2a trial is recruiting[13][15]

More background sits on the MOTS-c research entry. Related mitochondrial peptides include humanin and SS-31.

Detailed human data

CB4211, a MOTS-c analog

CB4211 is the clinical-stage analog that CohBar developed from MOTS-c. Its phase 1a and 1b trial, NCT03998514, is the only registered human program in which a MOTS-c analog was injected, and its results come from a company press release and investor slides, not a peer-reviewed paper.[10][11][12]

Swipe the table sideways to see every column.

CB4211 phase 1a/1b details
ItemPopulation or timingWhat was reported
Phase 1a65 healthy adults in 6 single-dose and 3 seven-day multiple-dose cohortsDoses not stated. A formulation change followed persistent local reactions at the injection site; injection-site reactions occurred in 79% on drug versus 33% on placebo[10][11]
Phase 1b: design23 adults with obesity and NAFLD randomized 1:1; 20 completed (CB4211 11, placebo 9); 3 stopped (2 for COVID-19, 1 consent)25 mg subcutaneously once daily for 4 weeks. The press release says 20 subjects; the slide deck gives 23 enrolled[10][11]
Phase 1b: liver enzymes and glucoseWeek 4, CB4211 versus placeboALT down 21% versus up 4%; AST down 28% versus down 11%; fasting glucose down 6% versus no change. Reported as significant by the sponsor[10][11]
Phase 1b: weight and liver fatWeek 4Weight showed a trend only. Liver fat fell about 5% in both arms, so there was no separation from placebo[10][11]
SafetyBoth partsNo serious adverse events reported. Injection-site reactions were the main adverse event[10][11]
StatusRegistry and later reportsRegistered as completed, 88 enrolled, 4 US sites, July 2018 to April 2021 per the registry[12]. Public Citizen told FDA’s advisory committee that development was discontinued[15]
CB4211 versus placebo at week 4: change in liver enzymes and fasting glucoseBar chart from sponsor reports of the phase 1b trial of CB4211, a MOTS-c analog, 25 mg once daily for 4 weeks. ALT fell 21 percent with CB4211 and rose 4 percent with placebo. AST fell 28 percent with CB4211 and 11 percent with placebo. Fasting glucose fell 6 percent with CB4211 and did not change with placebo. About 20 participants completed the trial.-30%-20%-10%0%10%Change from baseline, percentdown 21%up 4%ALTdown 28%down 11%ASTdown 6%no changeFasting glucoseCB4211 25 mg dailyPlaceboPhase 1b, adults with obesity and NAFLD, 4 weeks. Sponsor-reported; not peer reviewed.
Percent change from baseline at week 4, as reported in the sponsor press release and investor presentation.[10][11] Twenty of 23 randomized people completed (CB4211 11, placebo 9), so these are small-sample numbers. CB4211 is an analog, not MOTS-c itself. Not a recommendation of any amount.

Reading it plainly: in 20 completers, liver enzymes and fasting glucose moved more with the drug than with placebo, while weight and liver fat did not separate. The slide deck and the press release disagree slightly on the group size (23 enrolled versus 20 subjects), and the data have never been through peer review.[10][11] Because CB4211 is an analog, the result cannot be assumed to apply to MOTS-c.

Natural MOTS-c in people

Swipe the table sideways to see every column.

Human observational studies of MOTS-c (nothing administered)
StudyPopulationFinding
Reynolds 202110 sedentary healthy menMuscle MOTS-c rose 11.9-fold after exercise; plasma rose 1.6-fold during and 1.5-fold after exercise. Nothing was injected[2]
Ramanjaneya 2019Healthy women and women with PCOSAn intravenous fat emulsion (Intralipid) raised plasma MOTS-c to 232% of baseline in controls and 349% in PCOS. Insulin blunted the rise[6]
Ikonomidis 2020121 adults with type 2 diabetes after revascularizationMOTS-c below 167 ng/ml predicted heart events over 2 years (relative risk 3.8). Observational, not a treatment study. Registered as NCT04027712[3][14]
Zempo 2021Meta-analysis of 3 cohorts, n = 27,527Men carrying the m.1382A>C (K14Q) variant had more type 2 diabetes. Mice given the K14Q peptide did not show the benefit seen with standard MOTS-c[4]
Kumagai 2021Human plasma samples plus mouse and cell workPlasma MOTS-c was inversely correlated with myostatin in people[5]

Registered trial of MOTS-c injections

NCT07505745, called MOTS-MET, is a phase 2a trial of subcutaneous MOTS-c versus placebo in 120 adults with prediabetes and BMI 27 to 40, for 12 weeks with follow-up to week 16. The main outcomes are the change in the Matsuda index, a measure of insulin sensitivity, and adverse events. It lists one site, Peking University Shenzhen Hospital, a start date of 2 February 2026, and a primary completion of 14 February 2027. The sponsor is Hudson Biotech, and the record gives no dose or regimen and has no results.[13] That sponsor has several other registrations with near-identical start dates, one site and copied-looking details, including a record that reuses the title and enrollment of a Lilly phase 3 trial, so I treat this entry as unconfirmed rather than as a mature developer program.

Animal research amounts

These amounts are per kilogram of mouse body weight. They are shown in the original units and should not be scaled to people.

Swipe the table sideways to see every column.

MOTS-c in animal studies
Research objectiveSpecies or modelAmount studiedFrequencyDurationRouteSource
Metabolic effectsCD-1 mice, normal diet5 mg/kg/dayTwice daily4 daysIntraperitonealLee 2015[1]
High-fat-diet obesityCD-1 mice0.5 mg/kg/dayDailyRespirometry at 3 weeks; 8 weeks of dietIntraperitonealLee 2015[1]
Glucose tolerance and clampMiceDose not stated in the text I read (about 30% higher glucose infusion rate)Daily7 daysIntraperitonealLee 2015[1]
Physical performance, youngYoung CD-1 mice5 mg/kg/dayDaily2 weeksIntraperitonealReynolds 2021[2]
Physical performance, diet-induced obesityCD-1 mice5 and 15 mg/kg/dayDaily15 mg/kg/day improved running after 10 days but not 7IntraperitonealReynolds 2021[2]
Physical performance, aged12 and 22 month old C57BL/6N mice15 mg/kg/dayDaily2 weeks; old mice ran about 2-fold longerIntraperitonealReynolds 2021[2]
Late-life lifespanMice from about 23.5 months15 mg/kg/dayDaily for 8 weeks, then 3 times per weekTo end of lifeIntraperitonealReynolds 2021: median lifespan +6.4%, maximum +7.0%, hazard ratio 0.654; the paper says larger cohorts are needed[2]
Pain (formalin test)ICR mice50 mg/kgSingleAcuteIntraperitonealYin 2020[7]
MemoryMiceCell-penetrating analog given intranasally or intravenously; amounts not in abstractNot in abstractNot in abstractIntranasal or intravenousJiang 2021: peripheral MOTS-c did not cross the blood-brain barrier[8]
Radiation lung injuryC57BL/6 mice, 20 Gy chestR13A-MOTS-c analog 5 mg/kgDaily2 weeksIntraperitonealZhang 2026[9]

Two details matter for anyone reading the community literature. First, the doses spanned a hundredfold, from 0.5 mg/kg/day for metabolic effects to 50 mg/kg for pain, and the 15 mg/kg/day dose took 10 days to improve running in obese mice but did not in 7.[1][2][7] Second, the lifespan result in old mice is a trend that the authors themselves say needs larger groups.[2] Jiang and colleagues also found that MOTS-c injected peripherally did not reach the brain, which is why they built a cell-penetrating analog for that work.[8]

Practitioner and community-reported protocols

These are the schedules people search for, reproduced as the pages state them. None comes from a clinical trial, and none should be read as validated guidance.

Swipe the table sideways to see every column.

Practitioner and community MOTS-c protocols
Reported objectiveAmount reportedFrequencyDurationRouteSource typeSource
General injectable protocol5 to 10 mg per injection2 to 3 times per week, or every 5 days4 to 6 weeks (20 or 30 day protocols), repeat 2 to 4 times a yearSubcutaneousCommunity, vendor or clinic reported (Tier 6)Peptide Protocol Wiki dosing page[16]
“Standard weekly”5 to 10 mg2 to 3 times per week4 to 10 weeksSubcutaneousCommunity, vendor or clinic reported (Tier 6)Wiki community page, 40 reports[17]
Weekly single dose10 mgOnce weeklyUp to 10 weeksSubcutaneousCommunity, vendor or clinic reported (Tier 6)Wiki community page[17]
Daily low dose1 mgDaily4 to 8 weeksSubcutaneousCommunity, vendor or clinic reported (Tier 6)Wiki community page[17]
TitrationStart 200 mcg, rise to 1000 mcg in 200 mcg stepsStep every 2 weeks10 weeksSubcutaneousCommunity, vendor or clinic reported (Tier 6)Wiki community page[17]
Starting amount0.5 to 1 mgOnce or twice dailyNot statedNot namedCommunity, vendor or clinic reported (Tier 6)Substack author, no credentials[18]
Every five days5 mg (20 mg total)Every 5 days20 daysNot namedCommunity, vendor or clinic reported (Tier 6)Substack author[18]
Weekly10 mg (40 mg total); 10 mg (100 mg total)Once weekly4 weeks; 10 weeksNot namedCommunity, vendor or clinic reported (Tier 6)Substack author[18]
Three times weekly5 mg (60 to 90 mg total)3 times per week4 to 6 weeksNot namedCommunity, vendor or clinic reported (Tier 6)Substack author[18]
Cycle ruleNot applicableNot applicable“No more than 8 weeks on, 4 weeks off”; platform form says 8 to 12 weeks then a 4 week pauseNot applicableCommunity, vendor or clinic reported (Tier 6)Substack author; telehealth consent form (name withheld)[18][20]

The wiki’s community page names Reddit threads (r/Peptides and r/longevity), blogs and websites as its pool of 40 reports, without attributing individual protocols to specific posts.[17] I could not open the Reddit and forum threads directly, so no individual forum post is cited. The platform consent form I read gives no milligram figure and says outright that a safe and effective human dose, a maximum safe dose and a treatment duration have not been established.[20]

For the arithmetic of turning a vial into a volume, use the reconstitution calculator and the units guide. No concentration is stated for any community protocol above, so no injection volume is calculated here.

Polished gold pistons firing inside a glass casing with flames and sparks around a golden engine heart

Escalation, timing, duration, routes

The only titration ladder is the wiki community page’s 200 mcg start rising to 1000 mcg over 10 weeks. It is a community report, with no source behind it.[17] CB4211 was given at a fixed 25 mg a day for 4 weeks, with no titration described.[10][11]

Cycling language is consistent and unsourced: weeks on, then weeks off, with 8 weeks on and 4 off the commonest wording.[18][20] The mouse data point the other way on pattern. Reynolds gave old mice daily doses for 8 weeks and then 3 times per week to the end of life.[2] The route in every animal study was injection into the abdominal cavity, which is not a human route. The registered trial uses subcutaneous injection, and the HHS draft policy covers subcutaneous or intramuscular forms only.[13][21] Whether MOTS-c is active by mouth or nasal spray has not been shown; the intranasal work used a modified analog.[8]

Combinations and stacks

Formally studied: none. Mechanistically plausible: the wiki lists SS-31, a humanin fragment and CJC-1295/ipamorelin as pairings, which is a rationale about energy metabolism and growth hormone, not a tested combination.[17] Community-reported: MOTS-c appears in named blends such as the NAD, MOTS-c and 5-amino-1MQ mix. I found no sourced per-component amounts for it. A popular stack is not a validated one.

Side effects, quality and sourcing risks

In humans, the only reported adverse events are for the analog. Injection-site reactions were the main one in the CB4211 trial, 79% on drug versus 33% on placebo in phase 1a, and the sponsor reported no serious adverse events.[10][11] A persistent local depot at the injection site led to a formulation change.[10] That is a lesson about analogs, and it does not tell us what injected MOTS-c itself would do.

FDA said compounded MOTS-c products “may pose significant risk for immunogenicity,” meaning the body could react to the peptide or to impurities, and that it lacks important safety information and has identified no human exposure data for MOTS-c.[23] Public Citizen’s testimony added a long-term worry: MOTS-c can move into the cell nucleus and affect gene expression, and no study has followed that for more than a few weeks.[15] Mouse doses also ran very high (up to 50 mg/kg), which sets few limits on what is safe at human-scale exposures.

Mislabeling, wrong concentration and contamination are risks for any unapproved peptide. The certificate of analysis guide covers what a test report does and does not show. I did not find a published purity survey of MOTS-c products.

Regulatory and development status

As checked on 2 November 2026, no MOTS-c drug is FDA-approved. MOTS-c does not appear in Categories 1, 2 or 3 of FDA’s interim list, updated 14 May 2026, but FDA’s Category 2 page names it among nominations withdrawn by the nominators.[23][24] A single nominator, Wells Pharmacy Network, proposed it, withdrew, and FDA still presented it to its Pharmacy Compounding Advisory Committee on 23 July 2026, proposing that neither MOTS-c free base nor MOTS-c acetate be placed on the 503A bulks list.[25][26] The uses FDA evaluated were obesity and osteoporosis.[25] I am not printing vote counts because the trade reports I found disagree and I did not find posted minutes.

The separate HHS draft policy on 503A enforcement discretion, a non-binding proposal published 30 October 2026 with comments due about two weeks later, lists MOTS-c acetate as item 4 of its Appendix A.[21][22] It covers subcutaneous and intramuscular injectable forms only, not the free base, and states that the advisory committee voted in favor of both forms while FDA’s drug center recommended against listing either. The conditions include a patient-specific prescription, a registered facility with a certificate of analysis, adverse event reporting, a label reading “This is a compounded drug product. Not for resale,” and a 510(k)-cleared syringe as the only device. Appendix B gives the identity but no limit on strength, frequency or duration.[21] The policy applies until a final rule addresses the substance. The HHS policy post and the FDA peptide status page explain these categories in plain terms; if the two disagree with this paragraph, trust the primary documents cited here. For a plain-language report on the same policy, see The Weight Loss Atlas report on the HHS enforcement discretion policy, and for the dated sequence of decisions, its peptide policy tracker.

For sport, MOTS-c is named in section S4.4.1 of the 2026 WADA Prohibited List under AMPK activators, as “mitochondrial open reading frame of the 12S rRNA-c (MOTS-c).”[27]

Golden engine heart with fiery pistons inside glass ringed by a glowing oval light track

What is not public

Not public: the dose and regimen in NCT07505745; the structure of CB4211 and the dose levels of its phase 1a; any peer-reviewed analysis of the CB4211 trial; the origin of the 5 to 10 mg community ladder; any pharmacokinetics of injected MOTS-c in people; its half-life; any dose-finding study; any safety data beyond a few weeks; and a purity survey of products. Also unknown is whether the Hudson Biotech registration represents an active program.[10][13][15]

Frequently asked questions

What is the MOTS-c dosage?

There is no established dose. The most-reported online schedule is 5 to 10 mg injected 2 to 3 times a week for 4 to 10 weeks, with a 1 mg daily variant, and no source traces those numbers to a study.[16][17]

How much MOTS-c was used in human trials?

No published trial gave MOTS-c itself to people. The related analog CB4211 was given as 25 mg subcutaneously once daily for 4 weeks in a phase 1b trial reported by the sponsor.[10][11]

How much MOTS-c was used in mice?

Studies used 0.5 mg/kg/day, 5 mg/kg/day, 15 mg/kg/day and 50 mg/kg (single dose for pain), all by injection into the abdominal cavity. Those are mouse amounts and do not convert to human amounts.[1][2][7]

What is a MOTS-c dosage chart for weeks on and off?

Reported cycles are 4 to 6 weeks, 8 weeks on and 4 off, or 8 to 12 weeks then a 4 week pause, all from community or platform pages. None is a clinical schedule.[16][18][20]

How often is MOTS-c injected?

Community sources report daily, every 5 days, 2 to 3 times a week or weekly. The mouse literature used daily dosing and later 3 times a week.[2][16][17]

Is there a MOTS-c clinical trial?

Yes, NCT07505745 is a phase 2a trial of subcutaneous MOTS-c in 120 adults with prediabetes. It lists no dose and has no results. The sponsor has other registrations with near-identical dates, so treat the record with caution.[13]

Is MOTS-c legal or FDA approved?

It is not approved. FDA proposed against putting it on the 503A bulks list, and the HHS draft policy would have FDA exercise enforcement discretion for compounded MOTS-c acetate injectables under conditions. Status is in flux.[21][25]

Is MOTS-c banned in sport?

Yes. It is named in section S4.4.1 of the 2026 WADA Prohibited List.[27]

What are MOTS-c side effects?

The only human data are for the analog CB4211: injection-site reactions in 79% on drug versus 33% on placebo in phase 1a, and no serious events reported. MOTS-c itself has no published human safety record.[10][11]

Is MOTS-c the same as humanin?

No. Both are mitochondria-derived peptides but they are different sequences. See the humanin entry on this site for its separate research record.

Bottom line

MOTS-c is interesting because it is a signal made by mitochondria that, in mice, improved insulin sensitivity and exercise capacity.[1][2] What is genuinely published for humans: levels rise with exercise, low levels track with heart events in diabetes, and a gene variant is linked with diabetes in men.[2][3][4] The one injected human program belongs to the analog CB4211 and is sponsor-reported.[10][11] What is merely reported online: 5 to 10 mg injected 2 to 3 times weekly, 10 mg weekly, 1 mg daily and titration ladders, none traceable.[16][17][18] What remains speculative: efficacy and safety of injected MOTS-c in any person, any link between mouse and human amounts, and the lifespan trend in old mice. Status: not approved, FDA opposed to bulks listing, a draft HHS policy that would apply enforcement discretion to an acetate injectable under conditions, and banned in sport.[21][25][27]

Keep reading

Sources

  1. Lee C, Zeng J, Drew BG, et al. The mitochondrial-derived peptide MOTS-c promotes metabolic homeostasis and reduces obesity and insulin resistance. Cell Metab. 2015;21(3):443-454. https://doi.org/10.1016/j.cmet.2015.02.009 PMID 25738459; PMC4350682. Published animal research (Tier 3). Amounts read from the full text.
  2. Reynolds JC, Lai RW, Woodhead JST, et al. MOTS-c is an exercise-induced mitochondrial-encoded regulator of age-dependent physical decline and muscle homeostasis. Nat Commun. 2021;12(1):470. https://doi.org/10.1038/s41467-020-20790-0 PMID 33473109; PMC7817689. Published animal research (Tier 3) and human observational (Tier 2). Amounts read from the full text.
  3. Ikonomidis I, Katogiannis K, Kyriakou E, et al. Beta-amyloid and mitochondrial-derived peptide-c are additive predictors of adverse outcome to high-on-treatment platelet reactivity in type 2 diabetics with revascularized coronary artery disease. J Thromb Thrombolysis. 2020;49(3):365-376. https://doi.org/10.1007/s11239-020-02060-4 PMID 32052315. NCT04027712. Human observational or registered human trial (Tier 2).
  4. Zempo H, Kim SJ, Fuku N, et al. A pro-diabetogenic mtDNA polymorphism in the mitochondrial-derived peptide, MOTS-c. Aging (Albany NY). 2021;13(2):1692-1717. https://doi.org/10.18632/aging.202529 PMID 33468709; PMC7880332. Human observational or registered human trial (Tier 2) with mouse work.
  5. Kumagai H, Coelho AR, Wan J, et al. MOTS-c reduces myostatin and muscle atrophy signaling. Am J Physiol Endocrinol Metab. 2021;320(4):E680-E690. https://doi.org/10.1152/ajpendo.00275.2020 PMID 33554779; PMC8238132. Human observational or registered human trial (Tier 2) with Tier 3 and 4 work.
  6. Ramanjaneya M, Jerobin J, Bettahi I, et al. Lipids and insulin regulate mitochondrial-derived peptide (MOTS-c) in PCOS and healthy subjects. Clin Endocrinol (Oxf). 2019;91(2):278-287. https://doi.org/10.1111/cen.14007 PMID 31066084. Human observational or registered human trial (Tier 2).
  7. Yin X, Jing Y, Chen Q, et al. The intraperitoneal administration of MOTS-c produces antinociceptive and anti-inflammatory effects through the activation of AMPK pathway in the mouse formalin test. Eur J Pharmacol. 2020;870:172909. https://doi.org/10.1016/j.ejphar.2020.172909 PMID 31926126. Published animal research (Tier 3).
  8. Jiang J, Chang X, Nie Y, et al. Peripheral administration of a cell-penetrating MOTS-c analogue enhances memory and attenuates A-beta or LPS-induced memory impairment through inhibiting neuroinflammation. ACS Chem Neurosci. 2021;12(9):1506-1518. https://doi.org/10.1021/acschemneuro.0c00782 PMID 33861582. Published animal research (Tier 3).
  9. Zhang YL, Huang G, Li SP, et al. LAT1-mediated delivery of engineered R13A-MOTS-c attenuates radiation-induced lung injury via Nrf2 activation and mitochondrial protection. Redox Biol. 2026;94:104204. https://doi.org/10.1016/j.redox.2026.104204 PMID 42142418; PMC13199819. Published animal research (Tier 3). Analog.
  10. CohBar. CohBar announces positive topline results from the phase 1a/1b study of CB4211 under development for NASH and obesity. Press release, 10 August 2021 (BioSpace copy). https://www.biospace.com/cohbar-announces-positive-topline-results-from-the-phase-1a-1b-study-of-cb4211-under-development-for-nash-and-obesity Sponsor announcement; not peer reviewed (Tier 2 data).
  11. CohBar. Investor presentation, August 2021 (exhibit 99.3 to SEC filing). https://www.sec.gov/Archives/edgar/data/1522602/000121390021041377/ea145151ex99-3_cohbar.htm Sponsor presentation; not peer reviewed (Tier 2 data).
  12. ClinicalTrials.gov. NCT03998514: phase 1a/1b study of CB4211. https://clinicaltrials.gov/study/NCT03998514 Registered human trial (Tier 2). Completed; enrollment 88.
  13. ClinicalTrials.gov. NCT07505745: MOTS-MET, phase 2a study of MOTS-c in prediabetes. Sponsor: Hudson Biotech. https://clinicaltrials.gov/study/NCT07505745 Registered human trial (Tier 2). Recruiting; no dose in record; sponsor registry anomalies noted in text.
  14. ClinicalTrials.gov. NCT04027712: observational study of MOTS-c levels in type 2 diabetes (Athens). https://clinicaltrials.gov/study/NCT04027712 Registered observational study (Tier 2).
  15. Public Citizen (AbuDagga A). Testimony to the FDA Pharmacy Compounding Advisory Committee, 23 July 2026. Written or oral testimony; direct link to be added. Advocacy testimony; not a study.
  16. Peptide Protocol Wiki Team. MOTS-c dosing. https://www.peptideprotocolwiki.com/peptides/mots-c/dosing Dated 29 January 2026 per the page. Community, vendor or clinic reported (Tier 6). References section empty; the site also lists vendors.
  17. Peptide Protocol Wiki Team. MOTS-c community reports. https://www.peptideprotocolwiki.com/peptides/mots-c/community Dated 16 February 2026 per the page. Community, vendor or clinic reported (Tier 6). Based on 40 reports that are not individually attributed.
  18. Derek. MOTS-c: the mitochondrial peptide. Research Radar, Substack, 4 March 2026. https://derekpruski.substack.com/p/mots-c-the-mitochondrial-peptide Community, vendor or clinic reported (Tier 6). No credentials stated; no citations.
  19. Peptide Dossier. MOTS-c dosage guide. Dated September 2026 per the site. https://peptidedossier.com/guides/mots-c-dosage/ Educational site; states it does not sell peptides. Conflicting reports (rejects circulating figures).
  20. Telehealth platform patient consent form for injectable MOTS-c, dated 30 October 2026 per the page. Platform name withheld, no link. Community, vendor or clinic reported (Tier 6). Gives no mg dose.
  21. U.S. Department of Health and Human Services. Enforcement discretion policy regarding 503A compounding using certain peptide bulk drug substances, with Appendices A and B. https://www.hhs.gov/sites/default/files/hhs-503a-peptide-enforcement-discretion-policy-appendix-b.pdf Regulator draft policy; non-binding.
  22. Federal Register notice 2026-22192, docket HHS-OASH-2026-0496 (public inspection copy). https://public-inspection.federalregister.gov/2026-22192.pdf Regulator notice.
  23. U.S. Food and Drug Administration. Certain bulk drug substances for use in compounding that may present significant safety risks (Category 2 and withdrawn nominations). https://www.fda.gov/drugs/human-drug-compounding/certain-bulk-drug-substances-use-compounding-may-present-significant-safety-risks Regulator statement.
  24. U.S. Food and Drug Administration. Categories of bulk drug substances nominated for 503A compounding (interim policy list), updated 14 May 2026. https://www.fda.gov/media/94155/download Regulator document.
  25. U.S. Food and Drug Administration. Briefing document, Pharmacy Compounding Advisory Committee, 23 to 24 July 2026. https://www.fda.gov/media/193342/download Regulator document.
  26. U.S. Food and Drug Administration. July 23 to 24, 2026 meeting of the Pharmacy Compounding Advisory Committee. https://www.fda.gov/advisory-committees/advisory-committee-calendar/july-23-24-2026-meeting-pharmacy-compounding-advisory-committee-07232026 Regulator meeting page.
  27. World Anti-Doping Agency. 2026 Prohibited List (federation-hosted copy of the final September 2025 text). https://www.segas.gr/wp-content/uploads/2025/11/2026list_en_final_clean_september_2025.pdf Anti-doping rule list; copy hosted on a federation site, not WADA.
  28. Wikipedia. MOTS-c. https://en.wikipedia.org/wiki/MOTS-c Secondary source (identifiers only). Confirm in a chemical database.
  29. PubChem. Compound CID 146675088 (MOTS-c). https://pubchem.ncbi.nlm.nih.gov/compound/146675088 Chemical database; only the title and formula loaded.

Educational reference only, not medical advice. This page documents amounts reported in published research and circulating online. It does not tell any reader what to take, and it does not say any amount is safe or effective. Talk to a qualified, licensed clinician about personal medical decisions.

Share thisFacebookXEmail
Image placeholder

PeptideBlog Editorial compiles and reviews published research, clinical trial data, and community-reported information on peptides so readers can see what is actually documented versus what is simply repeated online. Every entry is sourced and evidence-graded. This is educational content, not medical advice.